Clinical Trial Update: IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on IBI376 in relapsed or refractory follicular lymphoma and marginal zone lymphoma. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• IBI376

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Indolent Non-hodgkin Lymphoma | Phase 2 | Status: COMPLETED